Salvati Elisa, Stellacci Francesco, Krol Silke
IFOM, The FIRC Institute for Molecular Oncology Foundation, IFOM-IEO Campus, Via Adamello 16, 20139 Milan, Italy.
Institute of Materials, École Polytechnique Fédérale de Lausanne, Station 12, CH-1015 Lausanne, Switzerland.
Nanomedicine (Lond). 2015;10(23):3495-512. doi: 10.2217/nnm.15.180. Epub 2015 Nov 26.
The use of nanotechnology for drug delivery in cancer therapy has raised high expectations. Additionally, the use of nanomaterials in sensors to extract and detect tumor specific biomarkers, circulating tumor cells, or extracellular vesicles shed by the tumor holds the promise to detect cancer much earlier and hence improve long-term survival of the patients. Moreover, the monitoring of the anticancer drug concentration, which has a narrow therapeutic window, will allow for a personalized dosing of the drug and will lead to improved therapeutic outcome and life quality of the patient. This review will provide an overview on the use of nanosensors for the early diagnosis of cancer and for the therapeutic drug monitoring, giving some examples. We envision nanosensors to make significant improvements in the cancer management as easy-to-use point-of-care devices for a broad population of users.
纳米技术在癌症治疗中的药物递送应用引发了人们的高度期望。此外,纳米材料在传感器中用于提取和检测肿瘤特异性生物标志物、循环肿瘤细胞或肿瘤释放的细胞外囊泡,有望更早地检测出癌症,从而提高患者的长期生存率。此外,对抗癌药物浓度的监测(其治疗窗口较窄)将实现药物的个性化给药,并改善治疗效果和患者的生活质量。本综述将概述纳米传感器在癌症早期诊断和治疗药物监测方面的应用,并给出一些实例。我们设想纳米传感器作为易于使用的即时检测设备,为广大用户群体在癌症管理方面带来显著改善。